A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E E4 Carriers. [For extension study, see profile 700227453]

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E E4 Carriers. [For extension study, see profile 700227453]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Jul 2014 Last checked against United Kingdom Clinical Research Network record.
    • 13 Nov 2012 UKCRN (Parent trial: 4368) reports trial status as 'active, no longer recruiting' and planned patient number as 800.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top